Solv, Trian
M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.
In January, activist investor Nelson Peltz's Trian Fund Management said in a letter to Solventum shareholders that the company's spin-off from 3M had not been living up to potential. Trian ...
The most notable increase was Solventum Corp (NYSE:SOLV), with an additional 1,336,564 shares, bringing the total to 8,462,819 shares. This adjustment represents a significant 18.76% increase in share ...
Nelson Peltz’s Trian Fund Management disclosed in an SEC filing its holdings as of December 31, 2024. Trian increased its stake in a number of ...
Unilever's board, which includes billionaire activist investor Nelson Peltz, was unified in its decision to oust CEO Hein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results